- | Pyxis Oncology
Will Pyxis Oncology Be Pfizer’s Fourth Billion-Dollar Spinout?
It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not. “There were a number of programs that had great clinical data, but unfortunately, did not have a development path within Pfizer,” she elaborates.
- | Alto Neuroscience
Mental health startup Cerebral teams with Alto Neuroscience to bring ‘precision psychiatry’ to patients’ homes
Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes.
- | MeiraGTx
A Biotech Unveils Its New Gene Control Technology
When she helped start MeiraGTx Holdings in 2015, CEO Zandy Forbes wanted to find a way to precisely control the output of genes implanted in people to fix genetic disorders. In an analyst meeting Wednesday, MeiraGTx unveiled that technology.
- | Scynexis
Ibrexafungerp: Paving the Way for Novel Candida Pharmacotherapy
It is estimated that 75% of women will experience an episode of vulvovaginal candidiasis (VVC) in their lifetimes, and with several OTC treatment options, incidence may be underreported.1,2 Based on the results of the VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) studies, ibrexafungerp (Brexafemme) was recently FDA approved for VVC treatment. It is a new, first-in-class triterpenoid antifungal and the first new antifungal class since the echinocandins were approved in the early 2000s.
- | OSE Immunotherapeutics
T-cell vaccines could top up immunity to COVID, as variants loom large
Peptide jabs targeting T cells could be especially useful for people with compromised immune systems, as backups for spike-based vaccines, or against Omicron and other emerging variants.
- | Scynexis
Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis
Scynexis sees a $300m-$400m commercial opportunity for the supplemental indication. A new therapeutic option is needed for oral step-down therapy because many Candida infections are resistant to oral fluconazole.
- | BeyondSpring Pharmaceuticals
Dr. Douglas Blayney, MD- Phase 3 PROTECTIVE-2 TRIAL
Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.
Sotio partners with Merck to test lead candidate with Keytruda; DC’s KeifeRx raises $6M in Series A — and brings on two new board members
Sotio has been on a roll lately. The quiet Czech biotech based in Prague got a massive $315 million raise last week, and now the biotech announced today that it’s joined in on a collaboration with Merck to evaluate a combo of Sotio’s lead candidate SOT101 with Merck’s PD-1 antibody Keytruda.
